In the first half of the year, 16 pharmaceutical companies' net profit growth rate exceeded 100% | 6 over 1 billion

Medical Network August 28th In late August, the A-share listed company's mid-year report disclosed intensive period. According to statistics, as of August 27, the total profit of six pharmaceutical companies in the first half of the year exceeded 1 billion yuan, respectively, Baiyun Mountain. Xinhecheng, Hengrui Medicine, Yunnan Baiyao, Huadong Medicine and WuXi PharmaTech; and a total of 16 net profit growth rates of over 100%, including Zhejiang Pharmaceutical, Zhifei Bio, Lukang Medicine, Watson Biotech, etc. Eye-catching.

Pharmaceutical enterprises with a net profit of over 500 million yuan in the first half of 2018 (unit: 100 million yuan)

Baiyunshan performance list (unit: 100 million yuan)

Baiyunshan's revenue in the first half of the year was 14.840 billion yuan, up 33.51% year-on-year; net profit was 2.619 billion yuan, up 126.14% year-on-year. According to the semi-annual report, the growth of performance on the one hand Baiyunshan further promoted the development of various business segments and increased market expansion. Driven the rapid development of the main business; on the other hand, Guangzhou medicine And the non-recurring income from the revaluation of the assets of Yixintang exceeds 1 billion yuan.

In the second half of the year, Baiyun Mountain will continue to promote the development of the Da Nan Pharmaceutical sector with 'large varieties'; in line with the 'product' font strategy of 'fashion, technology, culture', and promote the development of the big health sector with 'category of products' as the core; 'Deep Plowing + Pioneering' is the main line, speeding up the development and development of modern pharmaceutical logistics extension services, accelerating the sinking of the terminal distribution business network, accelerating the expansion of the pharmaceutical retail business, and promoting the large commercial sector; accelerating the expansion of new business and new formats, and actively creating features, Differentiated medical service industry, build a high-level medical e-commerce system, accelerate the promotion medical instruments The project has landed. In addition, it has also created a model of combined research and development, increased capital operation, and promoted investment projects in four major sectors.

List of achievements of Xinhecheng (Unit: 100 million yuan)

In the first half of the year, Xinhecheng's performance grew steadily, with revenue of 4.651 billion yuan, a year-on-year increase of 78.34%; net profit of 2.059 billion yuan, an increase of 251.32%; gross profit margin of 64.54%, an increase of more than 20 percentage points compared with the same period last year. Hecheng said that the growth in performance was mainly due to the increase in product sales prices.

In the first half of the year, Xinhecheng optimized its marketing model. The fragrance increased by 56.73% year-on-year, and the nutrition products achieved a growth rate of 86.98%. Increased research and development efforts to enhance the core competitiveness of the products; promoted the construction of manufacturing systems, and solidified the management experience of the company. Construction, speeding up the transformation and upgrading, Shandong Methionine Project and Heilongjiang Fermentation Project progressed steadily as planned, and the PPS industrial chain construction project progressed steadily.

Hengrui Pharmaceuticals Performance List (Unit: 100 million yuan)

In the first half of the year, the net profit of Hengrui Pharmaceutical reached 1.910 billion yuan, a year-on-year increase of 21.38%, and the gross profit margin was 86.61%. For the growth of performance, Hengrui Medicine said that the first step is the gradual gain of innovation; the second is the export represented by cyclophosphamide. The products are sold steadily in foreign markets. Third, the product structure is optimized. Non-anti-tumor drugs represented by surgical anesthesia, contrast agents and characteristic infusions gradually expand the market in their respective therapeutic fields and continue to maintain stable growth.

It is understood that Hengrui's domestic sales business is mainly carried out by the parent company, its holding subsidiary Jiangsu Kexin Pharmaceutical Sales Co., Ltd. and its wholly-owned subsidiary Jiangsu Xinchen Pharmaceutical Co., Ltd.; the holding subsidiary Jiangsu Kexin is mainly engaged in the company's own production. (including Shanghai Hengrui) anti-tumor drugs, specialty infusions, contrast agents, cardiovascular drugs and other wholesale sales; Jiangsu Xinchen is mainly engaged in the company's self-produced surgical anesthesia drugs wholesale sales.

Yunnan Baiyao Performance List (Unit: 100 million yuan)

Yunnan Baiyao is based on 'medicine' and continues to promote the 'new white medicine, big health' strategy. By building brand clusters of medicines, health products and traditional Chinese medicine resources, it has achieved a leap from 'product management' to 'industry management'. Developed into a well-known large-scale pharmaceutical and health enterprise integrating production and manufacturing, new drug research and development, drug circulation services, Chinese medicine resource development, nutrition and health care, and health care. In the first half of the year, the company's revenue was 12.974 billion yuan, an increase of 8.47%; net profit 16.33 100 million yuan, a year-on-year increase of 4.35%. It is understood that Yunnan Baiyao mainly includes medicines, health products, Chinese medicine resources and pharmaceutical business four business boards.

According to the analysis of the brokerage, after the completion of the mixed reform, Yunnan Baiyao expects that the governance, decision-making mechanism, and salary incentives will continue the market orientation and further enhance the enthusiasm of the employees. In addition, the company's brand of white medicine and rich industrial resources, the future focus on medical and medical In the large field, after the incentives are optimized, the operational vitality and long-term business space are expected to be further improved. The capacity integration capability is further strengthened, and the extension is expected to open up space.

List of Huadong Pharmaceutical Performance (Unit: 100 million yuan)

Huadong Pharmaceutical's revenue in the first half of the year was 15.325 billion yuan, up 8.76% year-on-year; net profit was 1.293 billion yuan, up 24.19% year-on-year. Its core subsidiaries, China-US East China key products maintained rapid growth, with revenue of 4.411 billion yuan, up 26.89% year-on-year. The net profit was 1.058 billion yuan, a year-on-year increase of 29.90%. The growth rate of the company's operating income decreased year-on-year, mainly due to the formal implementation of the two-vote system in Zhejiang Province, resulting in the loss of the business of distribution in commercial distribution. The above effects are expected to increase gradually in the second half of the year.

It is understood that China and the United States East China has formed a series of products in the four major areas of chronic kidney disease, transplant immunity, endocrine, digestive system, etc. There are 7 products with sales scale of more than 100 million yuan, including two 20 billion yuan. The pound-level products Bailing Capsule (fermented Cordyceps sinensis powder) and Kaboping (acarbose tablets). In addition, the company strengthens new product research and development, focusing on developing and upgrading competition in the fields of anti-tumor, super antibiotics and cardiovascular and cerebrovascular diseases. Advantage.

WuXi PharmaTech's performance at a glance (Unit: 100 million yuan)

WuXi PharmaTech's performance in the first half of the year increased rapidly, with a net profit of 1.272 billion yuan, a year-on-year increase of 71.31%. It is worth mentioning that its net profit in 2017 was 1.227 billion yuan, which means that the net profit in the first half of the year has exceeded that of last year.

WuXi PharmaTech said that the growth in performance was due to the continuous increase in the business volume of existing customers and the continuous expansion of new customers. More than 800 new customers were added to each segment. On the other hand, most of the company’s business income came from overseas. In dollar terms, the average exchange rate of the RMB in the first half of the year has a greater impact on the company's business operations. For example, based on the average exchange rate of the same period last year, the main business income increased by 27.87% compared with last year.

Pharmaceutical enterprises with a net profit growth rate of over 100% in the first half of 2018 (unit: 100 million yuan)

In the first half of the year, the net profit growth of 16 pharmaceutical companies such as Zhejiang Pharmaceutical, Zhifei Bio, Lukang Pharmaceutical, and Watson Bio was very eye-catching. It is worth mentioning that the growth rate of Zhifei Bio and Watson Bio is the growth rate of the two vaccine companies. At the forefront, however, just entering the second half of the year, the longevity biological vaccine incident was exposed, and the vaccine industry was again turbulent. Can the performance of the company be as 'floating red' as the first half of the year? Some insiders pointed out that the impact of adverse events However, it is only a short-term negative, it will take some time to recover, but it will not change the overall development trend of the pharmaceutical industry, and the regulation of the pharmaceutical industry will become stricter in the future.

Zhejiang Pharmaceutical: The company's performance has increased significantly mainly due to the market price of vitamin A in the first quarter. The market price of vitamin E has risen to a certain extent. The specialty drug, vancomycin hydrochloride, has been sold after the FDA lifted the warning letter in November 2017. In the same period of the year, the production capacity was gradually released. The production line of vitamin A and vitamin D3 in Changhai Industrial Park was officially put into operation in April this year. Healthy food Production license, lutein chewable tablets 5 and natural vitamin E soft capsules Health care products Formal production began in April; Changhai Pharmaceutical's main raw materials, minocycline, tigecycline, and daptomycin, began commercial export sales.

Lukang Pharmaceutical: The sharp increase in performance was on the one hand, the increase in operating income. In the first half of the year, affected by the flu epidemic, the sales revenue of preparation products increased by a large margin year-on-year; the raw material medicines were affected by the environmental protection suspension of production, and the market vacancies were large. The company expanded the sales revenue of raw materials. On the other hand, the company's new park economic operation, cost reduction, and efficiency improvement. In addition, the sales revenue of the growth subsidiaries achieved a significant increase in profits, which increased by 31.42% and 84.37% respectively.

Watson Bio: In the first half of the year, the company's performance turned losses into profit, mainly to expand its own vaccine business and strengthen marketing management. Its self-produced vaccine product sales continued to grow steadily. At present, the company mainly produces and sells its own vaccine products with influenza B hobby. Hemobacterial conjugate vaccine (bottle type and pre-filled type), 23-valent pneumococcal polysaccharide vaccine and other 6 products. Subsidiary Shanghai Zerun is mainly engaged in research and development and industrialization of new vaccine products such as HPV vaccine and recombinant hand, foot and mouth disease vaccine. .

for drug Quality risks and countermeasures, Watson Bio said, on the one hand, the production process of drugs is complex and involves a wide range, especially for biological products. On the other hand, biological products are also more demanding in circulation than ordinary drugs. High, even if all the links strictly follow the existing standardization documents for production and circulation, objectively there is still the probability of product failure. In order to prevent this risk, the company will simultaneously carry out industrialization in the clinical research stage of new products. Research, solve the problem of process stability in mass production, and minimize the risk of drug quality. At the same time, the subsidiary has set up a risk management department to adopt scientific risk management techniques and methods for risk identification in production management and quality management. And prevention, risk-based management of the entire production process according to the requirements of the new GMP.

Source: Listed company semi-annual report